Xeltis
Summary active Updated Jul 28, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Xeltis is an Eindhoven, Netherlands-based medtech company (with US operations) developing transformative bioabsorbable implants that enable the natural creation of living and long-lasting vessels and heart valves. The company’s lead product, aXess™, is a vascular access conduit for hemodialysis patients; the platform also includes the XABG (coronary artery bypass) and XPAD (pediatric heart valve) programs 1. Eliane Schutte serves as Chief Executive Officer 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-28 | Growth | €20.5M | Horizon 3 Healthcare | European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita, existing shareholders 1 |
This funding builds on the nearly €50M secured in 2025 from the European Investment Bank and existing shareholders 12. Proceeds will fund the US pivotal trial and FDA submission for aXess™, European commercial rollout, and advancement of the XABG and XPAD clinical programs.
What Investors Say
“The data generated by Xeltis has been highly compelling and underscores the potential of aXess™ to transform hemodialysis.”
— Matt McNamara, Chief Investment Officer, Horizon 3 Healthcare, July 2026 1
“Xeltis is pioneering a different approach” — enabling implants to gradually transform into patient tissue.
— Hermann Hauser, European Innovation Council Board Member, July 2026 1
What Founders Say
“This fundraising enables us to bring our groundbreaking vascular access technology to more European patients and advance our aXess™ pivotal trial in the US.”
— Eliane Schutte, CEO, Xeltis, July 2026 1
Sources
-
The Manila Times / GlobeNewswire, “Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch,” July 28, 2026. Accessed July 2026. https://www.manilatimes.net/2026/07/28/tmt-newswire/globenewswire/xeltis-raises-an-additional-205m-of-funding-to-advance-axess-toward-fda-approval-and-us-commercial-launch/2392733↩↩↩↩↩↩↩
-
Xeltis company announcement, “Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess,” 2025. Accessed July 2026. https://xeltis.com/xeltis-secures-nearly-e50m-from-the-european-investment-bank-eib-and-existing-shareholders-to-advance-axess-to-the-market/↩